Skip to main content
SpringerLink
Log in

Second-line treatment of metastatic prostatic carcinoma

  • Original Paper
  • Published:
Urological Research Aims and scope Submit manuscript

Abstract

Second-line palliative treatment of patients who have failed hormone therapy for advanced prostate cancer remains an important challenge in this disease. Very few agents have been shown to have a positive impact on survival, and toxicity is often therapy limiting in this elderly group of patients. Improvements in pain and performance status with maintenance of a reasonable functional status are worthwhile goals of any therapy at this stage. The earlier diagnosis of progressive disease from a rising prostate-specific antigen (PSA), and the use of validated quality of life questionnaires, can lead to useful improvements in the quality of the lives of these patients whose quantity we cannot at present lengthen.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bradbury D, King ED, Eddy H, Kyprianou N (1996) BCL-2 over expression delays radiation induced apoptosis in human prostate cancer cells. J Urol 155:215 (Abstract 796)

    Google Scholar 

  2. Brausi M, Jones WG, Fosså SD, et al (1995) High dose epirubicin is effective in measurable metastatic prostate cancer: a phase II study of the EORTC GU-Group. Eur J Cancer 31A:1622

    Google Scholar 

  3. Collste LG (1990) Second line treatment in hormone refractory prostate cancer. In: Newling DWW, Jones W (eds) EORTC GU-Group Monograph 7, prostate cancer and testicular cancer. Wiley Liss, New York, pp 29–37

    Google Scholar 

  4. Daugherty RL, Cockett ATK, Schoen SR, Schluss PM (1992) Suramin inhibits gonadotropin action in rat testes; implications for treatment of advanced prostatic cancer. J Urol 147:727

    Google Scholar 

  5. De Voogt HJ (1985) Second line endocrine management — anti androgens and anti oestrogens. In: Schröder FH, Richards B (eds) EORTC GU-Group Monograph 2. Therapeutic principles in metastatic prostate cancer. Alan R. Liss, New York, pp 351–357

    Google Scholar 

  6. Eisenberger MA (1990) Chemotherapy for endocrine resistant cancer of the prostate. In: Schröder FH (ed) EORTC GUGroup Monograph 8. Treatment of prostate cancer — facts and controversies. Wiley Liss, New York, pp 155–164

    Google Scholar 

  7. Eisenberger MA (1996) J Nat Cancer Inst

  8. Fosså SD, Jahnsen JU, Kolsen S, et al (1985) High dose MPA vs prednisolone in hormone resistant prostatic cancer. Eur Urol 11:11

    Google Scholar 

  9. Geldof AA, v.d. Tillaar, Rao BR, et al (1996) The effect on survival of the early administration of Rhenium 139 in a rat metastatic prostate cancer model. Urology (submitted)

  10. Hall SJ, Mutchnick SE, Schaker M, Timme TL, Chen SH, Woo SLC, Thompson TC (1996) Adenovirus mediated herpes simplex virus thymidine kinase gene transduction and ganciclovir treatment for prostate cancer: suppression of metatastasis in an orthotopic model and synergism with androgen ablation. J Urol 155:230 (abstract 871)

    Google Scholar 

  11. Hartley-Asp B (1993) Cytotoxic and antimitotic effect of estramustine in vivo. Cell Pharm 1 [Suppl 1]:559

    Google Scholar 

  12. Jones WG, Fosså SD, Bono AV, et al (1986) MMC in the treatment of metastatic prostate cancer: report of an EORTC phase II study. World J Urol 4:182

    Google Scholar 

  13. Jones WG, Fosså SD, Bono AV (1987) EORTC GU-Group phase II study of low dose weekly epirubicin in metastatic prostatic cancer. Cancer Treat Rep 71:1317

    Google Scholar 

  14. Keuppens F, Fossa SD, Nowe P, Denis L (1984) Secondary orchiectomy in patient with prostatic cancer in replapse. In: Denies L, Murphy GP, Prout GR, Schröder FH (eds) Contr. clinical trials in urology. Raven Press, New York, pp 207–221

    Google Scholar 

  15. Konyves I (1989) Estramustine phosphate (Estracyt) in the treatment of prostatic carcinoma. Int J Urol Nephrol 4:393

    Google Scholar 

  16. Kuil CW, Brinkman AO (1996) Androgen, anti androgen and androgen receptor abnormalities. Eur Urol 29 [Suppl 2]:78

    Google Scholar 

  17. Mahler C, Denis L (1995) Treatment of hormone refractory disease. Semin Surg Oncol 11:770

    Google Scholar 

  18. Mahler C, Denis L, De Coster RC (1989) The effects of a new imidazole derivative in advanced prostate cancer — a prelimenary report. In: Murphy G, Khoury S (eds) Therapeutic advances in urological oncology. Alan R. Liss, New York, pp 205–209

    Google Scholar 

  19. Marotto J, Lopez-Pacios MA, Ahmad A, et al (1991) Treatment of hormone refractory prostate cancer with estramustine phosphate (in Spanish). Act Urol Esp 15:421

    Google Scholar 

  20. Maulard C, Richard P, Droz JP, Jessueld D, Thomas F, Housset M (1993) A phase I/II of the somatostatin analogue somatalin in hormone refractory on prostate cancer (HRPC). Eur J Cancer 29a:327

    Google Scholar 

  21. Newling DWW (1996) Hormochemotherapis as primary treatment in advanced prostate-cancer? Euro Urol Today (Suppl) Vol. 6 No. 4

  22. Newling DWW, Denis L, Vermeylen K (1993) Orchiectomy vs goserelin + flutamide in the treatment of newly diagnosed metastatic prostate cancer. Cancer 72 [Suppl 12]:3793

    Google Scholar 

  23. Newling DWW, Fosså SD, Turn UW, Kurth KH, De Pauw M, Sylvester R (1994) MMC vs estramustine in the treatment of hormone resistant metastatic prostate cancer: the final analysis of the EORTC GU-Group prospective randomized phase III study (30865) J Urol 150:1840–1844

    Google Scholar 

  24. Parmar H, Bottomley G, Lloyd G (1993) Somatostin analogue (Somatulin) in hormone resistant prostate cancer. Eur J Cancer 29a:328

    Google Scholar 

  25. Porter AT, Nieman AST, Powe JE, et al (1993) Results of a randomized phase III trials to evaluate the efficacy of strontium 89 adjuvant to local field radiotherapy in the management of endocrine resistant prostate cancer. Int J Rad Oncol Biol Phys 25:805

    Google Scholar 

  26. Pummer K, Lenhert M, Seemann HL (1993) Chemohormonal and immunohormonal approaches in advanced prostatic carcinoma. Eur Urol 24 [Suppl 2]:81

    Google Scholar 

  27. Schally AV, Redding TW (1987) Somatostatin analogues as adjunct to LHRH in the treatment of experimental prostatic cancer. Proc Natl Acad Sci USA 84:7275

    Google Scholar 

  28. Scher HE, Kelly AK (1993) Flutamide withdrawal syndrome — its impact on clinical trials in hormone refractory prostate cancer. J Clin Oncol 11:1566

    Google Scholar 

  29. Schröder FH (1988) Current concepts in the management of prostatic cancer. In: Smith PH, Pavone-Macaluso (eds) Management of advanced cancer of prostate and bladder. Alan R. Liss, New York, pp 3–12

    Google Scholar 

  30. Schuurman MG, Schulze H, Pastor J, Haupt G, Herde Th, Senge Th (1996) Relationship of response to suramin treatment and survival in hormone refractory prostate cancer. J Urol 155:293 (abstract 1202)

    Google Scholar 

  31. Small EJ, Smnivas S (1995) The anti androgen withdrawal syndrome. Cancer 78:1428

    Google Scholar 

  32. Sridhara R, Eisenberger MA, Siribaldi VJ, Reyno LM, Egorin MJ (1995) Evaluation of prostate specific antigen as a surrogate marker for response of hormone-refractory prostate-cancer to suramin therapy J Clin Oncol 13:2944–2953

    Google Scholar 

  33. Winnan Ewing M, Laocca RV, Stein CA, Myers CE, Lineham WM (1989) Effect of Suramin on proliferation of human prostatic carcinoma. Proc Am Assoc Cancer Res 30:310

    Google Scholar 

  34. Zelefsky MJ, Scher HI, Forman JD, et al (1989) Palliative hemiskeletal irradiation of widespread metastatic prostate cancer — a comparison of single and fractionated regimes. Int J Rad Oncol Biol 17:1281

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Academic Hospital of the Free University, De Boelelaan 1117, Postbus 7057, NL-1007 MB, Amsterdam, The Netherlands

    D. W. W. Newling

Authors
  1. D. W. W. Newling
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Newling, D.W.W. Second-line treatment of metastatic prostatic carcinoma. Urol. Res. 25 (Suppl 2), S73–S78 (1997). https://doi.org/10.1007/BF00941992

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00941992

Key words

Search

Navigation